Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma

Hepatology

Volumn 60, Issue 4, 2014, Pages 1241-1250

  Malz, Mona ^a,g   Bovet, Michael ^a   Samarin, Jana ^a   Rabenhorst, Uta ^b,h   Sticht, Carsten ^c   Bissinger, Michaela ^a   Roessler, Stephanie ^a   Bermejo, Justo Lorenzo ^a   Renner, Marcus ^a   Calvisi, Diego Francesco ^d   Singer, Stephan ^a,e   Ganzinger, Matthias ^a   Weber, Achim ^f   Gretz, Norbert ^c   Zörnig, Martin ^b   Schirmacher, Peter ^a   Breuhahn, Kai ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF GREIFSWALD   (Germany)

^e EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; FAR UPSTREAM ELEMENT BINDING PROTEIN; FAR UPSTREAM ELEMENT BINDING PROTEIN INTERACTING REPRESSOR; REPRESSOR PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR DP1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA HELICASE; FUBP1 PROTEIN, HUMAN; ISOPROTEIN; POLY-U BINDING SPLICING FACTOR 60KDA; RNA BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CELL DEDIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 8Q; CONTROLLED STUDY; EXON; GENE EXPRESSION PROFILING; GENE LOCUS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR XENOGRAFT; ANIMAL; CELL DIFFERENTIATION; CELL MOTION; COMPARATIVE STUDY; DRUG EFFECTS; GENETICS; LIVER TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SCID MOUSE; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; DNA HELICASES; DNA-BINDING PROTEINS; EXONS; HUMANS; IN VITRO TECHNIQUES; LIVER NEOPLASMS; MICE, SCID; MICE, TRANSGENIC; PROTEIN ISOFORMS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION FACTOR DP1; TRANSPLANTATION, HETEROLOGOUS;

EID: 84927799921     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27218     Document Type: Article

References (26)

1. Malz M, Pinna F, Schirmacher P, Breuhahn K. Transcriptional regulators in hepatocarcinogenesis-key integrators of malignant transformation. J Hepatol 2012;57:186-195.
2. Zubaidah RM, Tan GS, Tan SB, Lim SG, Lin Q, Chung MC. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008;8:5086-5096.
3. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO, et al. Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 2009;50:1130-1139.
4. Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, et al. Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 2009;50:1121-1129.
5. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, et al. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 2009;69:2234-2243.
6. Zhang Z, Harris D, Pandey VN. The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol 2008;82:5761-5773.
7. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D, et al. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell 2001;104:353-363.
8. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, Weber A, et al. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 2006;25:2119-2130.
9. Cukier CD, Hollingworth D, Martin SR, Kelly G, Diaz-Moreno I, Ramos A. Molecular basis of FIR-mediated c-myc transcriptional control. Nat Struct Mol Biol 2010;17:1058-1064.
10. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H, et al. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res 2006;66:1409-1417.
11. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, et al. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PLoS One 2010;5:e9983.
12. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, Lee JS, et al. A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 2010;70:10202-10212.
13. Roessler S, Long EL, Budhu A, Chen Y, Zhao X, Ji J, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology 2012;142:957-966 e912.
14. Bouffard P, Barbar E, Briere F, Boire G. Interaction cloning and characterization of RoBPI, a novel protein binding to human Ro ribonucleoproteins. RNA 2000;6:66-78.
15. Zhang J, Chen QM. Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene 2013;32:2907-2916.
16. Conner EA, Lemmer ER, Omori M, Wirth PJ, Factor VM, Thorgeirsson SS. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis. Oncogene 2000;19:5054-5062.
17. Brauckhoff A, Malz M, Tschaharganeh D, Malek N, Weber A, Riener MO, et al. Nuclear expression of the ubiquitin ligase seven in absentia homolog (SIAH)-1 induces proliferation and migration of liver cancer cells. J Hepatol 2011;55:1049-1057.
18. Moinzadeh P, Breuhahn K, Stutzer H, Schirmacher P. Chromosome alterations in human hepatocellular carcinomas correlate with aetiology and histological grade-results of an explorative CGH meta-analysis. Br J Cancer 2005;92:935-941.
19. Datta A, Nag A, Raychaudhuri P. Differential regulation of E2F1, DP1, and the E2F1/DP1 complex by ARF. Mol Cell Biol 2002;22:8398-8408.
20. Martin K, Trouche D, Hagemeier C, Kouzarides T. Regulation of transcription by E2F1/DP1. J Cell Sci Suppl 1995;19:91-94.
21. Winzen R, Thakur BK, Dittrich-Breiholz O, Shah M, Redich N, Dhamija S, et al. Functional analysis of KSRP interaction with the AU-rich element of interleukin-8 and identification of inflammatory mRNA targets. Mol Cell Biol 2007;27:8388-8400.
22. Kajiwara T, Matsushita K, Itoga S, Tamura M, Tanaka N, Tomonaga T, et al. SAP155-mediated c-myc suppressor far-upstream element-binding protein-interacting repressor splicing variants are activated in colon cancer tissues. Cancer Sci 2013;104:149-156.
23. Hsiao HH, Nath A, Lin CY, Folta-Stogniew EJ, Rhoades E, Braddock DT. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry 2010;49:4620-4634.
24. Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology 2011;53:2112-2121.
25. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752-1763.
26. Huth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B, et al. NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter. J Med Chem 2004;47:4851-4857.